Impact of Nirsevimab on Respiratory Syncytial Virus Bronchiolitis in Hospitalized Infants: A Real-World Study

• 2024

  Log in to bookmark this resource.

  Log in
• Eric Jeziorski; Antoine Ouziel; Marie Cotillon; Constance Bridonneau; Etienne Bizot; Clément Basse
PMID: 39589139DOI: https://dx.doi.org/10.1097/INF.0000000000004630

---

Access Resources

• Journal ArticleEN
• Ask aRCie About This Resource

About

This study looks at the impact of nirsevimab, a monoclonal antibody, on infants hospitalized with respiratory syncytial virus (RSV) bronchiolitis. It describes how immunized infants had fewer hospitalizations and less severe symptoms compared to non-immunized ones. The research was conducted in France and involved 1085 infants under 12 months old. Nirsevimab showed high effectiveness in reducing RSV-related hospital stays by one day and lowering the need for oxygen support. The study suggests that using nirsevimab could lead to significant health benefits and cost savings by preventing severe RSV cases in young children.

---

Tags

Focus Area: Infectious Disease

Audiences: Nurses; Physicians

Emergency Management Stages: Response; Preparedness (Prevention / Protection)

Bundles: Nirsevimab Library

Keywords: Bronchiolitis; France; Hospitalization; Immunization; Infant; Length of Stay; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Oxygen Inhalation Therapy; Antibodies, Monoclonal, Humanized

Institutions: Groupe de Pathologie Infectieuse Pediatrique; Université de Montpellier; Hôpital Femme Mère Enfant Service des Urgences Pédiatriques; Hôpital Louis Mourier; Hôpital enfant-adolescent-CHU de Nantes; Hôpital Antoine-Béclère AP-HP

---

More like this

Hospital Guidelines for Management of Pediatric Patients in Disasters 2015 · Northwest Healthcare Response Network A Timely Assessment of Pediatric Surge Capacity and Capability 2023 · Pediatric Pandemic Network (PPN), Nationwide Children's Hospital, The Ohio State University Impact of Tele-Emergency Consultations on Pediatric Interfacility Transfers: A Cluster-Randomized Crossover Trial 2023 · University of California, Davis

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---